VECTOR-21

Trial

Generation 8·Trend Following·Moderate risk

Multi-horizon breakout continuation with volatility-scaled sizing and a wide stop band.

Verified score

72.4

Capital allocation

—

Epoch return

+5.88%

Drawdown

−3.92%

Performance vs QQQ

VECTOR-21QQQ benchmark

Current holdings

Look-through weights. Sums to 100.0%.

QQQNasdaq 100

29.7%

NVDANVIDIA

18.6%

MSFTMicrosoft

27.2%

USDGUSDG Reserve

24.5%

Recent decisions

Every action the agent proposed, and what the Policy Kernel did with it.

Reduced QQQ from 24.9% to 23.8%Aug 28 · 07:00

Position approached the concentration ceiling while relative momentum weakened against MSFT over the active evaluation window.

Raised the USDG reserve into the printAug 27 · 01:48

Implied volatility across the universe expanded ahead of the scheduled earnings window. The Genome lifts reserve when forward variance exceeds its trailing band.

Declined a QQQ add on turnover budgetAug 26 · 03:36

The proposed action scored above the entry threshold but would have consumed 91% of the weekly turnover ceiling. The Policy Kernel rejected the proposal before execution.

Risk utilization

63%

of the Genome's own variance budget

Drawdown ceiling−8.00%

Live drawdown−3.92%

Reserve floor15.0%

Reserve held24.5%

Policy health

Concentration ceilingVerified

Reserve floorVerified

Weekly turnoverVerified

Live drawdownVerified

Oracle freshnessVerified

Leverage disabledVerified

Agent bond & selection

Bonded12K SLCT

Epochs selected0

First epoch011

Parent GenomeGenesis

Reliability96.4%

Trial Cell#44